The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.
Degenerative Disc Disease
The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
-
Alabama Ortho, Spine and Sports, PC, Birmingham, Alabama, United States, 35235
Premier Surgery Center, Concord, California, United States, 94520
Source Healthcare, Santa Monica, California, United States, 90403
Bold City Clinical Research, Jacksonville, Florida, United States, 32224
Meta Medical Research Institute, LLC, Dayton, Ohio, United States, 45432
Clinical Investigations, LLC, Edmond, Oklahoma, United States, 73034
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Mesoblast, Ltd.,
Roger D Brown, STUDY_DIRECTOR, Mesoblast, Ltd.
2027-10